Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 589, Issue 1-3, Pages 306-314Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2008.04.047
Keywords
type 2 diabetes mellitus; alogliptin; dipeptidyl peptidase-4; incretin; glucagon-like peptide-1
Categories
Funding
- Takeda San Diego, Inc., San Diego, California, USA
- Takeda Pharmaceutical Company, Ltd., Osaka, Japan
Ask authors/readers for more resources
The aim of the present research was to characterize the pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel quinazolinone-based dipeptidyl peptidase-4 (DPP-4) inhibitor. Alogliptin potently inhibited human DPP-4 in vitro (mean IC(50), similar to 6.9 nM) and exhibited > 10,000-fold selectivity for DPP-4 over the closely related serine proteases DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidase, and tryptase (IC(50) > 100,000 nM). Absolute oral bioavailability of alogliptin in rats, dogs, and monkeys was 45%, 86%, and 72% to 88%, respectively. After a single oral dose of alogliptin, plasma DPP-4 inhibition was observed within 15 min and maximum inhibition was > 90% in rats, dogs, and monkeys; inhibition was sustained for 12 h in rats (43%) and dogs (65%) and 24 h in monkeys (> 80%). From E(max) modeling, 50% inhibition of DPP-4 activity was observed at a mean alogliptin plasma concentration (EC(50)) of 3.4 to 5.6 ng/ml (10.0 to 16.5 nM) in rats, dogs, and monkeys. In Zucker fa/fa rats, a single dose of alogliptin (0.3,1,3, and 10 mg/kg) inhibited plasma DPP-4(91% to 100% at 2 h and 20% to 66%at 24 h), increased plasma GLP-1 (2- to 3-fold increase in AUC(0-20) in) and increased early-phase insulin secretion (1.5- to 2.6-fold increase in AUC(0-20) min) and reduced blood glucose excursion (31%-67% decrease in AUC(0-90) min) after oral glucose challenge. Alogliptin (30 and 100 mg/kg) had no effect on fasting plasma glucose in normoglycemic rats. In summary, these data suggest that alogliptin is a potent and highly selective DPP-4 inhibitor with demonstrated efficacy in Zucker fa/fa rats and potential for once-daily dosing in humans. (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available